Axial length, refraction, and retinal vascularization 1 year after ranibizumab or bevacizumab treatment for retinopathy of prematurity
Chun-Ju Lin,1,2 Yi-Yu Tsai1,2 1School of Medicine, College of Medicine, China Medical University, Taichung, Taiwan; 2Department of Ophthalmology, China Medical University Hospital, China Medical University, Taichung, Taiwan Purpose: The purpose of this study was to report on the axial length, refrac...
Guardado en:
Autores principales: | Lin CJ, Tsai YY |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2016
|
Materias: | |
Acceso en línea: | https://doaj.org/article/ce50a7fda98f4a9faa716882e547e831 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Short-Term Changes in Intraocular Pressure After Intravitreal Injection of Bevacizumab for the Treatment of Retinopathy of Prematurity
por: Obata S, et al.
Publicado: (2019) -
Growth and neurodevelopmental status in patients with retinopathy of prematurity treated with intravitreal bevacizumab: a case–control study
por: Majid Abrishami, et al.
Publicado: (2021) -
Metabolism in Retinopathy of Prematurity
por: Yohei Tomita, et al.
Publicado: (2021) -
Grid laser with modified pro re nata injection of bevacizumab and ranibizumab in macular edema due to branch retinal vein occlusion: MARVEL report no 2
por: Narayanan R, et al.
Publicado: (2016) -
Aflibercept versus Ranibizumab as a Second Line Therapy After Bevacizumab for Diabetic Macular Edema
por: Alsaedi NG, et al.
Publicado: (2021)